Table 1 Baseline characteristics
Missing | Non-SGLT2i | SGLT2i | p value | |
|---|---|---|---|---|
n (%) | n = 52 | n = 29 | ||
Age, years | 69 ± 12 | 65 ± 9 | 0.139 | |
Women, n (%) | 10 (19) | 8 (28) | 0.386 | |
Height, cm | 163 ± 9 | 163 ± 7 | 0.812 | |
Weight, kg | 64.3 ± 14.0 | 66.8 ± 17.3 | 0.489 | |
Body mass index, kg/m2 | 24.0 ± 4.1 | 25.0 ± 5.3 | 0.353 | |
Systolic blood pressure, mmHg | 114 ± 16 | 112 ± 18 | 0.55 | |
Diastolic blood pressure, mmHg | 66 ± 10 | 69 ± 11 | 0.208 | |
Heart rate, bpm | 68 ± 12 | 68 ± 9 | 0.960 | |
NYHA, n (%) | 0.454 | |||
1 | 7 (14) | 6 (21) | ||
2 | 24 (46) | 15 (52) | ||
3 | 21 (40) | 8 (28) | ||
Ischemic etiology, n (%) | 25 (48) | 9 (31) | 0.14 | |
Comorbidity, n (%) | ||||
Hypertension | 37 (71) | 22 (76) | 0.648 | |
Dyslipidemia | 38 (73) | 20 (69) | 0.694 | |
LVEF, % | 42.2 ± 2.1 | 35.1 ± 2.9 | 0.049 | |
HFrEF, n (%) | 26 (50) | 21 (72) | 0.050 | |
Laboratory Data | ||||
Albumin, mg/dl | 3.5 ± 0.5 | 3.8 ± 0.5 | 0.014 | |
Hemoglobin, mg/dl | 12.5 ± 2.0 | 13.3 ± 2.2 | 0.118 | |
eGFRcre, mL/min/1.73m2 | 55.3 ± 22.0 | 51.9 ± 20.6 | 0.503 | |
eGFRcys, mL/min/1.73m2 | 8 (10) | 56.8 ± 23.0 | 56.0 ± 24.5 | 0.890 |
NT-proBNP, pg/ml | 2,909 ± 6,413 | 3,099 ± 8,053 | 0.907 | |
Uric acid, mg/dl | 6.0 ± 1.4 | 5.7 ± 1.8 | 0.551 | |
Fasting blood glucose, mg/dl | 2 (2) | 112 ± 34 | 119 ± 39 | 0.433 |
Insulin, mIU/mL | 3 (4) | 8.1 ± 6.7 | 6.8 ± 5.4 | 0.371 |
HbA1c, % | 1 (1) | 6.8 ± 0.9 | 7.1 ± 1.0 | 0.234 |
Medication, n (%) | ||||
RASi | 30 (58) | 20 (69) | 0.317 | |
Beta blocker | 40 (77) | 24 (83) | 0.536 | |
MRA | 24 (46) | 14 (48) | 0.854 | |
Loop diuretics | 33 (63) | 20 (69) | 0.618 | |
DPP4i | 20 (38) | 15 (52) | 0.248 | |
Biguanides | 1 (2) | 6 (21) | 0.004 | |
Insulin | 7 (13) | 6 (21) | 0.396 | |